AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29923136 — intervention group
Group type: EXPERIMENTAL
Intervention: Geospatial risk assessment system using SEPA topsoil data
Number of subjects: 173
Study 29923136 — intervention group
Group type: EXPERIMENTAL
Intervention: Geospatial risk assessment system using SGU biogeochemical data
Number of subjects: 173
Study 29923136 — intervention group
Group type: EXPERIMENTAL
Intervention: Geospatial risk assessment system using SGU geophysical data
Number of subjects: 173
Study 29923136 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuzzy classification for risk assessment
Number of subjects: 173
Study 25524052 — intervention group
Group type: EXPERIMENTAL
Intervention: TV-1380
Number of subjects: 0
Study 23837430 — intervention group
Group type: EXPERIMENTAL
Intervention: Written handover cognitive aid
Number of subjects: 20
Study 23837430 — intervention group
Group type: COMPARATOR
Intervention: Standard practice
Number of subjects: 20
Study 23028596 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-meal protein drinks (PMPD) containing whey protein isolates (9 g protein)
Number of subjects: 14
Study 23028596 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-meal protein drinks (PMPD) containing soy protein isolates (9 g protein)
Number of subjects: 14
Study 23028596 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-meal protein drinks (PMPD) with added amino acids (iso, leu, lys, thr, val)
Number of subjects: 14
Study 23028596 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-meal protein drinks (PMPD) with added amino acids + arg
Number of subjects: 14
Study 23028596 — intervention group
Group type: COMPARATOR
Intervention: Reference meal (water provided 250 ml)
Number of subjects: 14
Study 23028596 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-meal protein drinks (PMPD)
Number of subjects: 14
Study 19776051 — intervention group
Group type: EXPERIMENTAL
Intervention: Niacinamide (250 mg twice daily, titrated to 750 mg twice daily)
Number of subjects: 15
Study 19776051 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 19776051 — intervention group
Group type: COMPARATOR
Intervention: Niacinamide vs Placebo
Number of subjects: 15
Study 17451408 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib
Number of subjects: 0
Study 17451408 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone
Number of subjects: 0
Study 15000754 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia
Number of subjects: 68
Study 15000754 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender (female)
Number of subjects: 68
Study 15000754 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 68
Study 15000754 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender effect
Number of subjects: 68
Study 15515533 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect laryngoscope (IL)
Number of subjects: 23
Study 15515533 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct laryngoscope (DL)
Number of subjects: 23
Study 10813237 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin
Number of subjects: 0
Study 10813237 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 0
Study 10073836 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 16 mg once daily
Number of subjects: 0
Study 10073836 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 32 mg once daily
Number of subjects: 0
Study 10073836 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2071085 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine 10 mg/day
Number of subjects: 24
Study 2071085 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem 3 x 60 mg/day
Number of subjects: 24
Study 6404238 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin sodium (n = 51)
Number of subjects: 103
Study 6404238 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline, n = 52)
Number of subjects: 103
Study 6404238 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost analysis with prophylactic antibiotics
Number of subjects: 103
Study 31504709 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole grain wheat (WGW) consumption (98 g/d) for 12 weeks
Number of subjects: 50
Study 31504709 — intervention group
Group type: COMPARATOR
Intervention: Refined wheat (RW) consumption
Number of subjects: 50
Study 30292535 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological counseling for 40 minutes with professional counselors
Number of subjects: 34
Study 30292535 — intervention group
Group type: COMPARATOR
Intervention: Chatting for 40 minutes with professional counselors
Number of subjects: 34
Study 26423328 — intervention group
Group type: EXPERIMENTAL
Intervention: Mop handle height at shoulder level
Number of subjects: 13
Study 26423328 — intervention group
Group type: EXPERIMENTAL
Intervention: Mop handle height at chin level
Number of subjects: 13
Study 26423328 — intervention group
Group type: COMPARATOR
Intervention: Mop handle height at eye level
Number of subjects: 13
Study 25025992 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 15-30 mg/day added on calcium channel blockers (CCBs)
Number of subjects: 73
Study 25025992 — intervention group
Group type: COMPARATOR
Intervention: Calcium channel blockers (CCBs) alone
Number of subjects: 73
Study 22328206 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-594 150 μg
Number of subjects: 266
Study 22328206 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-594 225 μg
Number of subjects: 266
Study 22328206 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-594 300 μg
Number of subjects: 266
Study 22328206 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 266
Study 22328206 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-594 (all doses)
Number of subjects: 266
Study 21111985 — intervention group
Group type: EXPERIMENTAL
Intervention: Model 1 (clinical factors + neurohormones)
Number of subjects: 190
Study 21111985 — intervention group
Group type: EXPERIMENTAL
Intervention: Model 2 (NT‐proBNP only)
Number of subjects: 190
Study 18845954 — intervention group
Group type: EXPERIMENTAL
Intervention: Community mobilization, mobile voluntary counseling and testing (VCT), and posttest support services
Number of subjects: 14657
Study 18845954 — intervention group
Group type: EXPERIMENTAL
Intervention: Unprotected intercourse in the previous 6 months
Number of subjects: 14657
Study 15975459 — intervention group
Group type: EXPERIMENTAL
Intervention: Trypan blue 1%
Number of subjects: 46
Study 15975459 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green 0.5%
Number of subjects: 46
Study 15975459 — intervention group
Group type: COMPARATOR
Intervention: Control without stain
Number of subjects: 46
Study 12756571 — intervention group
Group type: EXPERIMENTAL
Intervention: ECC (180 degrees s(‐1))
Number of subjects: 24
Study 12756571 — intervention group
Group type: EXPERIMENTAL
Intervention: ECC (30 degrees s(‐1))
Number of subjects: 24
Study 12756571 — intervention group
Group type: COMPARATOR
Intervention: CON
Number of subjects: 24
Study 10211504 — intervention group
Group type: EXPERIMENTAL
Intervention: Total pelvic floor repair
Number of subjects: 24
Study 10211504 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluteus maximus transposition
Number of subjects: 24
Study 7985367 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance angiography (MR angiography)
Number of subjects: 48
Study 2735330 — intervention group
Group type: EXPERIMENTAL
Intervention: sucralfate 2 g twice daily for six weeks
Number of subjects: 0
Study 2735330 — intervention group
Group type: EXPERIMENTAL
Intervention: ranitidine 300 mg at bedtime
Number of subjects: 0
Study 2735330 — intervention group
Group type: EXPERIMENTAL
Intervention: pentagastrin 0.1 and 6.0 micrograms/kg/hour or histamine acid phosphate 4.0 and 40 micrograms/kg/hour (secretory stimulants)
Number of subjects: 0
Study 1097221 — intervention group
Group type: EXPERIMENTAL
Intervention: Loxapine succinate
Number of subjects: 50
Study 1097221 — intervention group
Group type: COMPARATOR
Intervention: Chlorpromazine
Number of subjects: 50
Study 30479044 — intervention group
Group type: EXPERIMENTAL
Intervention: Silymarin 1% gel
Number of subjects: 40
Study 30479044 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 28436572 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg delayed-release cysteamine bitartrate
Number of subjects: 96
Study 28436572 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 25900350 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa (100 mg administered at each session for five sessions over 1 week)
Number of subjects: 0
Study 25900350 — intervention group
Group type: COMPARATOR
Intervention: Placebo (administered at each session for five sessions over 1 week)
Number of subjects: 0
Study 22555988 — intervention group
Group type: EXPERIMENTAL
Intervention: Training-only group (34 carers)
Number of subjects: 107
Study 22555988 — intervention group
Group type: EXPERIMENTAL
Intervention: Training-plus-screening protocol group (35 carers)
Number of subjects: 107
Study 22555988 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (38 carers)
Number of subjects: 107
Study 19949165 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (10 mg)
Number of subjects: 145
Study 19949165 — intervention group
Group type: COMPARATOR
Intervention: Placebo followed by Donepezil (10 mg)
Number of subjects: 145
Study 18248656 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubiprostone 16 microg b.d.
Number of subjects: 195
Study 18248656 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubiprostone 32 microg b.d.
Number of subjects: 195
Study 18248656 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubiprostone 48 microg b.d.
Number of subjects: 195
Study 18248656 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubiprostone (all doses)
Number of subjects: 195
Study 18248656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 195
Study 16803749 — intervention group
Group type: EXPERIMENTAL
Intervention: Body‐Mind‐Spirit (BMS) intervention
Number of subjects: 0
Study 16803749 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive‐Expressive (SE) intervention
Number of subjects: 0
Study 16803749 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Support Self‐Help (SS) intervention
Number of subjects: 0
Study 16803749 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 0
Study 12950856 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen lysine salt (OKi) suppositories
Number of subjects: 85
Study 12950856 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol
Number of subjects: 85
Study 11063410 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance engineers (exposed group)
Number of subjects: 31
Study 11063410 — intervention group
Group type: COMPARATOR
Intervention: Computer programmers (controls)
Number of subjects: 31
Study 8726291 — intervention group
Group type: EXPERIMENTAL
Intervention: Various interventions in gastroenterology
Number of subjects: 200
Study 1303113 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% chlorhexidine gel delivered with toothpicks
Number of subjects: 7
Study 1303113 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 7
Study 3891033 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine (60 micrograms X kg‐1)
Number of subjects: 15
Study 3891033 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 15
Study 3891033 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine
Number of subjects: 15
Study 29565643 — intervention group
Group type: EXPERIMENTAL
Intervention: Keeping the shoulder pads in place
Number of subjects: 26
Study 29565643 — intervention group
Group type: EXPERIMENTAL
Intervention: Keeping the chinstrap in place
Number of subjects: 26
Study 29565643 — intervention group
Group type: EXPERIMENTAL
Intervention: Using a bag-valve mask versus a pocket mask
Number of subjects: 26
Study 26551445 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938 (1 × 10 colony forming units daily)
Number of subjects: 184
Study 26551445 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical appearing)
Number of subjects: 184
Study 24177146 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive bias modification (CBM-I) training to generate positive interpretations of ambiguous social scenarios
Number of subjects: 55
Study 24177146 — intervention group
Group type: COMPARATOR
Intervention: Placebo control condition generating 50% positive and 50% negative interpretations
Number of subjects: 55
Study 24177146 — intervention group
Group type: COMPARATOR
Intervention: Neutral placebo control group generating neutral, non-emotional situations
Number of subjects: 55
Study 22559011 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic comprising two strains of lactobacilli and two strains of bifidobacteria, one capsule daily for 21 days
Number of subjects: 0
Study 22559011 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo, one capsule daily for 21 days
Number of subjects: 0
Study 20484917 — intervention group
Group type: EXPERIMENTAL
Intervention: semi-standardised acupuncture plus rescue medication (cetirizine)
Number of subjects: 400
Study 20484917 — intervention group
Group type: COMPARATOR
Intervention: penetrating sham acupuncture at non-acupuncture points plus rescue medication
Number of subjects: 400
Study 20484917 — intervention group
Group type: COMPARATOR
Intervention: rescue medication alone for 8 weeks (standard treatment group)
Number of subjects: 400
Study 18545766 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group 1
Number of subjects: 405
Study 18545766 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group 2
Number of subjects: 405
Study 18545766 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 405
Study 18545766 — intervention group
Group type: COMPARATOR
Intervention: Control only
Number of subjects: 405
Study 18545766 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive persuasive strategy
Number of subjects: 405
Study 18545766 — intervention group
Group type: EXPERIMENTAL
Intervention: Moral obligation
Number of subjects: 405
Study 16048984 — intervention group
Group type: EXPERIMENTAL
Intervention: Nelfinavir alone
Number of subjects: 0
Study 16048984 — intervention group
Group type: EXPERIMENTAL
Intervention: Nelfinavir and efavirenz (combination)
Number of subjects: 0
Study 16048984 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz alone
Number of subjects: 0
Study 12588057 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (exercise program)
Number of subjects: 21
Study 12588057 — intervention group
Group type: COMPARATOR
Intervention: Non-participating anorexics
Number of subjects: 21
Study 12588057 — intervention group
Group type: EXPERIMENTAL
Intervention: Unaffected subjects participating in exercise program
Number of subjects: 21
Study 10398355 — intervention group
Group type: EXPERIMENTAL
Intervention: Ten-point clock test
Number of subjects: 71
Study 10398355 — intervention group
Group type: COMPARATOR
Intervention: Elderly controls
Number of subjects: 71
Study 7537287 — intervention group
Group type: EXPERIMENTAL
Intervention: risperidone 4 mg
Number of subjects: 59
Study 7537287 — intervention group
Group type: EXPERIMENTAL
Intervention: risperidone 8 mg
Number of subjects: 59
Study 7537287 — intervention group
Group type: COMPARATOR
Intervention: clozapine 400 mg
Number of subjects: 59
Study 7537287 — intervention group
Group type: EXPERIMENTAL
Intervention: risperidone (both doses)
Number of subjects: 59
Study 7537287 — intervention group
Group type: COMPARATOR
Intervention: clozapine
Number of subjects: 59
Study 7537287 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 59
Study 7537287 — intervention group
Group type: EXPERIMENTAL
Intervention: risperidone
Number of subjects: 59
Study 2045855 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin (400 mg/m2)
Number of subjects: 120
Study 2045855 — intervention group
Group type: COMPARATOR
Intervention: Iproplatin (300 mg/m2)
Number of subjects: 120
Study 7019932 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg emepronium bromide 3-times daily
Number of subjects: 0
Study 7019932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31265147 — intervention group
Group type: EXPERIMENTAL
Intervention: EXTOD education programme
Number of subjects: 0
Study 31265147 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilot study
Number of subjects: 0
Study 30554211 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiration® Valve System (SVS) and medical management
Number of subjects: 107
Study 30554211 — intervention group
Group type: COMPARATOR
Intervention: Standard medical management alone
Number of subjects: 107
Study 28869885 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic index for 6-month mortality
Number of subjects: 0
Study 28869885 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic index for 12-month mortality
Number of subjects: 0
Study 26765556 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow sensor
Number of subjects: 110
Study 26765556 — intervention group
Group type: COMPARATOR
Intervention: ETCO2 detector
Number of subjects: 110
Study 25438609 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of fall-related concerns
Number of subjects: 260
Study 25438609 — intervention group
Group type: COMPARATOR
Intervention: Low levels of fall-related concerns
Number of subjects: 260
Study 25438609 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of fall-related concerns at 14 months
Number of subjects: 260
Study 25438609 — intervention group
Group type: COMPARATOR
Intervention: Low levels of fall-related concerns at 14 months
Number of subjects: 260
Study 21836528 — intervention group
Group type: EXPERIMENTAL
Intervention: TXA (10 mg/kg at induction followed by 1 mg/kg/h infusion)
Number of subjects: 76
Study 21836528 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 76
Study 19445057 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkalinized lignocaine
Number of subjects: 150
Study 19445057 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic saline
Number of subjects: 150
Study 19445057 — intervention group
Group type: COMPARATOR
Intervention: Air
Number of subjects: 150
Study 17891081 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 15152819 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental Floss
Number of subjects: 55
Study 15152819 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpick Holder
Number of subjects: 55
Study 11674982 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS monitoring group (n = 20)
Number of subjects: 40
Study 11674982 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 20)
Number of subjects: 40
Study 9299382 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Stroop stimuli (e.g., the word 'RED' displayed in a green font)
Number of subjects: 0
Study 9299382 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroop stimuli with colored symbols
Number of subjects: 0
Study 9299382 — intervention group
Group type: COMPARATOR
Intervention: Control condition designed to elicit nonspecific interference (taboo words displayed in color fonts)
Number of subjects: 0
Study 7924129 — intervention group
Group type: EXPERIMENTAL
Intervention: RCCT (Randomized Concentration-Controlled Trials)
Number of subjects: 0
Study 7924129 — intervention group
Group type: EXPERIMENTAL
Intervention: RCCT
Number of subjects: 0
Study 7924129 — intervention group
Group type: COMPARATOR
Intervention: RDCT
Number of subjects: 0
Study 3295553 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine (n = 28)
Number of subjects: 53
Study 3295553 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 25)
Number of subjects: 53
Study 31743436 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Navigator LIVESTRONG Cancer Navigation Services (PN-LCNS)
Number of subjects: 288
Study 31743436 — intervention group
Group type: COMPARATOR
Intervention: Patient Navigator only (PN only)
Number of subjects: 288
Study 29035394 — intervention group
Group type: EXPERIMENTAL
Intervention: A-NKC/A-CD14+HLA-DRDIM ratio of ⩾0.29
Number of subjects: 111
Study 29035394 — intervention group
Group type: COMPARATOR
Intervention: A-NKC/A-CD14+HLA-DRDIM ratio of <0.29
Number of subjects: 111
Study 29035394 — intervention group
Group type: EXPERIMENTAL
Intervention: A-NKC/A-CD14+HLA-DRDIM ratio
Number of subjects: 111
Study 27517350 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide (LCM) 150mg, b.i.d.
Number of subjects: 60
Study 27517350 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine immediate‐release (CBZ‐IR) 200mg, t.i.d.
Number of subjects: 60
Study 24837060 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnobehavioral therapy (HypBe)
Number of subjects: 60
Study 24837060 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnobehavioral therapy enhanced by energetic psychotherapy (HypEn)
Number of subjects: 60
Study 24837060 — intervention group
Group type: COMPARATOR
Intervention: HypEn
Number of subjects: 60
Study 23957874 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer‐ and family‐based group therapies
Number of subjects: 0
Study 23957874 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 0
Study 20659947 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombus aspiration (TA)
Number of subjects: 299
Study 20659947 — intervention group
Group type: COMPARATOR
Intervention: Standard PCI (SP)
Number of subjects: 299
Study 18779881 — intervention group
Group type: COMPARATOR
Intervention: Histamine skin prick test
Number of subjects: 0
Study 18779881 — intervention group
Group type: COMPARATOR
Intervention: Codeine skin prick test
Number of subjects: 0
Study 18779881 — intervention group
Group type: EXPERIMENTAL
Intervention: New prick tests after 7 days
Number of subjects: 0
Study 16781290 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% tacrolimus ointment
Number of subjects: 0
Study 16781290 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 0
Study 12531775 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 8
Study 12531775 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 10726794 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 255
Study 10726794 — intervention group
Group type: COMPARATOR
Intervention: Timolol
Number of subjects: 255